Corvus Pharmaceuticals Inc (CRVS) concluded trading on Wednesday at a closing price of $4.70, with 14.06 million shares of worth about $66.1 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 146.07% during that period and on December 18, 2024 the price saw a loss of about -36.40%. Currently the company’s common shares owned by public are about 62.58M shares, out of which, 50.33M shares are available for trading.
Stock saw a price change of -42.05% in past 5 days and over the past one month there was a price change of -43.65%. Year-to-date (YTD), CRVS shares are showing a performance of 167.05% which increased to 205.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.30 but also hit the highest price of $10.00 during that period. The average intraday trading volume for Corvus Pharmaceuticals Inc shares is 800.81K. The stock is currently trading -41.97% below its 20-day simple moving average (SMA20), while that difference is down -41.88% for SMA50 and it goes to 15.04% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) currently have 62.58M outstanding shares and institutions hold larger chunk of about 28.59% of that.
The stock has a current market capitalization of $302.01M and its 3Y-monthly beta is at 0.98. It has posted earnings per share of -$0.93 in the same period. It has Quick Ratio of 0.92 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRVS, volatility over the week remained 15.68% while standing at 8.60% over the month.
Stock’s fiscal year EPS is expected to drop by -65.36% while it is estimated to increase by 49.24% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on August 18, 2023 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Corvus Pharmaceuticals Inc (CRVS) stock as a Buy in their note to investors on December 01, 2021, suggesting a price target of $8 for the stock. On May 27, 2021, Cantor Fitzgerald Initiated their recommendations, while on February 10, 2021, Mizuho Downgrade their ratings for the stock with a price target of $4. Stock get a Buy rating from Mizuho on September 12, 2019.
